Summary
The AI claims substantially conflict with the supplied FDA label excerpt. The provided label text concerns TURALIO (pexidartinib), but many claims in the user list (e.g., PTCL, IV use, antibody-drug conjugate, CD25 targeting, and specific dosing schedule) are not supported by the supplied label and appear to reflect a different product/mechanism.
Category Scores
Accurate Statements
TURALIO can cause serious and potentially fatal liver injury, including vanishing bile duct syndrome (VBDS), and liver injury can occur despite monitoring and prompt drug cessation.
Supported by label section 5.1 Hepatotoxicity.
TURALIO is only available through a restricted program under a REMS because of risk of hepatotoxicity.
Supported by label section 5.2 TURALIO REMS Program.
Unsupported Statements
Turalio (nalfotamab mafodotin-ejfv) is used to treat adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who have received at least one prior systemic therapy.
No indication text for PTCL or adult relapsed/refractory use is present in the supplied FDA label excerpts.
Turalio is administered intravenously.
Supplied label excerpt indicates oral capsule dosing/modification context (e.g., 125 mg orally twice daily); IV administration is not supported.
Turalio is approved for adult patients with relapsed or refractory PTCL who have previously undergone at least one line of systemic treatment.
No approval/indication details for PTCL appear in the supplied excerpts.
PTCL is a group of aggressive non-Hodgkin lymphomas.
No definitional/clinical description of PTCL appears in the supplied label excerpts.
Turalio is an antibody-drug conjugate.
No such formulation description appears in the supplied label excerpts.
Turalio targets the CD25 protein found on certain cancer cells.
No target/mechanism (CD25) appears in the supplied label excerpts.
Turalio’s antibody component delivers a chemotherapy agent directly to cancer cells to help kill them.
No antibody/ADC mechanism appears in the supplied label excerpts.
Common side effects of Turalio include fatigue.
No list of common adverse reactions (including fatigue) is provided in the supplied excerpts.
Common side effects of Turalio include fever.
No list of common adverse reactions (including fever) is provided in the supplied excerpts.
Common side effects of Turalio include rash.
No list of common adverse reactions (including rash) is provided in the supplied excerpts.
Common side effects of Turalio include diarrhea.
No list of common adverse reactions (including diarrhea) is provided in the supplied excerpts.
Common side effects of Turalio include nausea.
No list of common adverse reactions (including nausea) is provided in the supplied excerpts.
Common side effects of Turalio include neutropenia (low white blood cell count).
No adverse reaction list in the supplied excerpts supports neutropenia as a common side effect.
Common side effects of Turalio include edema (swelling).
No adverse reaction list in the supplied excerpts supports edema as a common side effect.
Patients may experience peripheral neuropathy with Turalio.
No peripheral neuropathy safety information appears in the supplied excerpts.
Peripheral neuropathy can cause numbness, tingling, or pain.
No neuropathy description appears in the supplied label excerpts.
Turalio is given as an intravenous infusion by a healthcare professional.
No administration route/infusion instruction appears in the supplied excerpts; hepatotoxicity management references oral dosing (125 mg orally twice daily).
The recommended starting dose of Turalio is 3.0 mg/kg administered every three weeks.
The supplied label excerpt discusses 125 mg orally twice daily and does not support mg/kg q3weeks dosing.
Specialty pharmacies provide comprehensive patient support services for complex and high-cost medications like Turalio, including assistance with insurance authorization, financial assistance programs, and patient education on administration and side effect management.
No REMS/specialty pharmacy support details for patient assistance are included in the supplied excerpts.
Because of administration requirements and potential side effects, Turalio is typically distributed through specialty pharmacies to ensure patients receive proper guidance and support.
The supplied excerpt only states availability through a restricted program under REMS; it does not state specialty pharmacy distribution or patient support services.
Turalio’s approval was based on the results of a clinical trial demonstrating efficacy in patients with relapsed or refractory PTCL.
No clinical trial/efficacy/indication for PTCL is present in the supplied excerpts.
The clinical trial assessed objective response rate and duration of response as key endpoints.
No endpoint details appear in the supplied excerpts.
Contradictions
High
AI Statement
Turalio is administered intravenously.
Label Reference
Contradicted by provided label excerpt referencing inability to tolerate “125 mg orally twice daily” (Dosage and Administration 2.2) and oral administration context; IV administration is not supported in the supplied label text.
High
AI Statement
Turalio (nalfotamab mafodotin-ejfv) is used to treat adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)...
Label Reference
The supplied label text pertains to TURALIO (pexidartinib) and contains hepatotoxicity/REMS content; no PTCL indication is included in the supplied excerpts, and the named active ingredient conflicts with the provided active ingredient for TURALIO (pexidartinib).
High
AI Statement
Turalio is an antibody-drug conjugate that targets CD25.
Label Reference
The supplied label text provides hepatotoxicity and REMS information for TURALIO (pexidartinib) and does not support an antibody-drug conjugate or CD25 targeting mechanism.
High
AI Statement
The recommended starting dose of Turalio is 3.0 mg/kg administered every three weeks.
Label Reference
Contradicted by supplied label excerpt referencing oral dose modification for “125 mg orally twice daily” (Dosage and Administration 2.2).
Important Omissions
Key hepatotoxicity monitoring and mitigation details (e.g., specific liver test monitoring frequency and dose withholding/reduction/discontinuation thresholds) are not reflected in the general safety-related claims listed; only one hepatotoxicity statement is present.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple claims conflict with the supplied prescribing information excerpt and/or are unsupported, including route of administration, dosing, and product/active ingredient mechanism/indication. Only hepatotoxicity/REMS statements are supported by the provided label text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Major mismatches with the supplied TURALIO (pexidartinib) label excerpt: indication, mechanism (ADC/CD25), route (IV), and dosing schedule are unsupported or contradicted by the provided label text.
Suggested Improvement
Remove or replace PTCL/ADC/CD25/IV and mg/kg q3weeks claims. Limit label-supported content to hepatotoxicity/REMS risk messaging and the oral dosing/monitoring-related instructions present in the supplied sections (5.1/5.2/2.2).